The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease

American Heart Journal

Volumn 146, Issue 6, 2003, Pages 1007-1014

  Carlquist, John F ^a,b   Muhlestein, Joseph B ^a,b   Horne, Benjamin D ^a   Hart, Noal I ^a   Bair, Tami L ^a   Molhuizen, Henri O F ^c,d   Anderson, Jeffrey L ^a,b  

^a LDS HOSPITAL   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNILEVER RESEARCH VLAARDINGEN   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CERIVASTATIN; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; GENE; GENOTYPE; HEART INFARCTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; STABLE ANGINA PECTORIS; TAQ1B GENE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0012605419     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00501-5     Document Type: Article

References (32)

1. Yen FT, Deckelbaum RJ, Mann CJ, et al. Inhibition of cholesteryl ester transfer protein activity by monoclonal antibody: effects on cholesteryl ester formation and neutral lipid mass transfer in human plasma. J Clin Invest 1989;83:2018-24.
2. Tall A. Plasma lipid transfer proteins. Ann Rev Biochem 1995;64: 235-57.
3. Hannuksela ML, Liinamaa MJ, Kesaniemi YA, et al. Relation of polymorphisms in the cholesteryl ester transfer protein gene to transfer protein activity and plasma lipoprotein levels in alcohol drinkers. Atherosclerosis 1994;110:35-44.
4. Agellon LB, Walsh A, Hayek T, et al. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J Biol Chem 1991;266:10796-801.
5. Marotti KR, Castle CK, Boyle TP, et al. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 1993;364:73-5.
6. Bruce C, Chouinard RA, Tall AR. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. Annu Rev Nutr 1998;18:297-330.
7. Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med 1998;338: 86-93.
8. Kuivenhoven JA, de Knijff P, Boer JM, et al. Heterogeneity at the CETP gene locus: influence on plasma CETP concentrations and HDL cholesterol levels. Arterioscler Thromb Vasc Biol 1997;17: 560-8.
9. Ballantyne CM, Herd JA, Dunn JK, et al. Effects of lipid lowering therapy on progression of coronary and carotid artery disease. Curr Op Lipidol 1997;8:354-61.
10. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
11. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100:230-5.
12. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
13. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996;348:1339-42.
14. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279: 1615-22.
15. Ross SD, Allen IE, Connelly JE, et al. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Int Med 1999;159:1793-802.
16. Contacos C, Barter PJ, Vrga L, et al. Cholesteryl ester transfer in hypercholesterolaemia: fasting and postprandial studies with and without pravastatin. Atherosclerosis 1998;141:87-98.
17. Guerin M, Lassel TS, Le Goff W, et al. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 2000;20:189-97.
18. Taylor GS, Muhlestein JB, Wagner GS, et al. Implementation of a computerized cardiovascular information system in a private hospital setting. Am Heart J 1998;136:792-803.
19. Anderson JL, King GJ, Thomson MJ, et al. A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction. J Am Coll Cardiol 1997;30:1206-11.
20. Drayna D, Lawn R. Multiple RFLPs at the human cholesteryl ester transfer protein (CETP) locus. Nucl Acids Res 1987;15:4698.
21. Evans RS, Pestotnik SL, Classen DC, et al. A computer-assisted management program for antibiotics and other antiinfective agents. N Engl J Med 1998;338:232-8.
22. Muhlestein JB, Horne BD, Bair TL, et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001;87:257-61.
23. Bernard S, Moulin P, Lagrost L, et al. Association between plasma HDL-cholesterol concentration and Taq 1 B CETP gene polymorphism in non-insulin-dependent diabetes mellitus. J Lipid Res 1998;39:59-65.
24. Ordovas JM, Cupples LA, Corella D, et al. Association of cholesteryl ester transfer protein-Taq1B polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol 2000;20:1323-9.
25. de Maat MP, Jukema JW, Ye S, et al. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol 1999;83:852-6.
26. Marian AJ, Safavi F, Ferlic L, et al. Interactions between angiotensin-1 converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study. J Am Coll Cardiol 2000;35:89-95.
27. Zambon A, Deeb SS, Brown BG, et al. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation 2001;103:792-8.
28. Brown BG, Zhao XQ, Sacco DE, et al. Atherosclerosis regression, plaque disruption, and cardiovascular events: a rationale for lipid lowering in coronary artery disease. Annu Rev Med 1993;44: 365-76.
29. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-13.
30. Horne BD, Muhlestein JB, Carlquist JF, et al. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol 2000;36:1774-80.
31. Gottlieb SS. Dead is dead - artificial definitions are no substitute. Lancet 1997;349:662-663.
32. Lloyd-Jones DM, Martin DO, Larson MG, et al. Accuracy of death certificates for coding coronary heart disease as the cause of death. Ann Intern Med 1998;129:1020-6.